Earnings digests and industry comparisons for Japan's biggest listed companies.
9 reports
Peptide Dream's first-half FY2026 revenue grew 8.0% to ¥9.226 billion, and its operating loss narrowed to ¥2.534 billion from ¥2.625 billion. Radiopharmaceuticals drove growth, cushioning drug discovery losses. It expects a full-year operating profit of ¥4.6 billion on ¥32 billion revenue.
Q2 FY2026 (Jan-Jun 2026)
Kobayashi's H1 FY2026 revenue rose 2.5% to ¥70,749 million, but operating profit fell 67.5% to ¥2,162 million amid beni-koji fallout and ad spending. Full-year net profit is seen surging 173.5% to ¥10,000 million on a share sale gain.
FY2026 H1 (January–June 2026)
Nippon Shinyaku posted a 24.1% year-on-year increase in revenue to 49,066 million yen for the first quarter of FY2027, driven by strong sales of new drugs Aririda and Fintepla. Operating profit rose 22.1% to 12,311 million yen, while net income attributable to owners of the parent climbed 22.5% to 10,109 million yen, a record first-quarter profit.
FY2027 Q1 (Apr-Jun 2026)
Eisai's revenue for the first quarter of FY2027 (April-June 2026) rose 15.6% to ¥234.3 billion, driven by robust global sales of its three key products: Lenvima, Leqembi, and Dayvigo. Net profit attributable to owners of the parent climbed 26.0% to ¥18.2 billion, while a weak yen also provided a tailwind.
FY2027 Q1 (Apr-Jun 2026)
Astellas posted Q1 FY2027 revenue of ¥640.9bn (+26.7% YoY), operating profit of ¥184.5bn (+94.9%) and net profit of ¥141.8bn (+107.3%). Strategic products PADCEV and IZERVAY, along with XTANDI, drove growth, supported by a weak yen. Full-year guidance was maintained, with Q1 progress at 28.9% for revenue and 46.7% for operating profit.
Q1 FY2027 (Apr-Jun 2026)
Kyowa Kirin's global revenue rose 15% to ¥145.2 billion in Q2 FY2026, while core operating profit surged 80% to ¥46.1 billion, driven by strong Crysvita sales and a weak yen. The core margin hit 31.8%.
FY2026 Q2 (Apr-Jun 2026)
Otsuka Holdings reported double-digit revenue and profit growth for the first half of fiscal 2026, driven by strong sales of Rexulti and new drug Voyzact, leading to a sharp upward revision of its full-year guidance.
FY2026 Q2 (Jan-Jun 2026)
Sumitomo Pharma reported a 19.9% jump in revenue to ¥129.5 billion for the first quarter of its fiscal year ending March 2027, but core operating profit fell 11.0% to ¥18.1 billion. The bottom line got a boost from a sharp swing to foreign exchange gains, lifting net profit 51.7% to ¥17.0 billion.
FY2027 Q1 (Apr-Jun 2026)
Takeda reported a 10.2% rise in revenue to ¥1,219.9 billion for the first quarter of FY2027, but the gain was entirely driven by a weaker yen; on a constant currency basis, revenue edged down 0.5%. Operating profit climbed 9.1% to ¥201.4 billion, while net income attributable to owners fell 8.9% to ¥113.2 billion, reflecting higher tax expenses.
Q1 FY2027 (Apr-Jun 2026)
